الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> Reverse Transcriptase>>Nevirapine-d4

Nevirapine-d4 (Synonyms: NVP-d4)

رقم الكتالوجGC47770

نيفيرابين- D4 يسمى الديوتيريوم نيفيرابين

Products are for research use only. Not for human use. We do not sell to patients.

Nevirapine-d4 التركيب الكيميائي

Cas No.: 1051418-95-1

الحجم السعر المخزون الكميّة
1 mg
427٫00
متوفر
5 mg
1280٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Nevirapine-d4 is intended for use as an internal standard for the quantification of nevirapine by GC- or LC-MS. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).1 It binds to HIV-1 reverse transcriptase and inhibits RNA plus-strand initiation (IC50 = 0.45 μM). Nevirapine prevents seroconversion and viremia in a chimpanzee model of HIV-1 infection.2 Formulations containing nevirapine have been used in combination therapy for the treatment of HIV-1 infection.

1.Grobler, J.A., Dornadula, G., Rice, M.R., et al.HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitroJ. Biol. Chem.282(11)8005-8010(2007) 2.Grob, P.M., Cao, Y., Muchmore, E., et al.Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptaseNat. Med.3(6)665-670(1997)

مراجعات

Review for Nevirapine-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nevirapine-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.